Dr. Xiaotong Guo 郭晓彤
Chief Physician, Associate Professor
Department of Thoracic Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of pulmonary nodules, lung cancer, esophageal cancer, and mediastinal tumors. Specializes in thoracoscopic minimally invasive surgery, including single-port lobectomy, segmentectomy, sleeve resection, pneumonectomy, and thoracoscopic-laparoscopic esophagectomy.
Dr. Guo is Chief Physician and Head of Thoracic Surgery at Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center. With over 20 years of experience and more than 10,000 surgeries, Dr. Guo trained under Academician Jie Dr. Guo and completed a postdoctoral fellowship at Peking Union Medical College. In 2017, Dr. Guo helped establish the hospital in Shenzhen.
Professional roles
- Youth Committee Member, Thoracic Surgery Branch, Chinese Medical Doctor Association
- Youth Committee Member, Esophageal Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Thoracic Surgery Professional Committee, Guangdong Pharmaceutical Association
- Deputy Leader, Esophageal Cancer Professional Group, Thoracic Surgery Branch, Guangdong Medical Doctor Association
Name order: in Chinese the family name comes first (Guo Xiaotong). Papers usually list the name as Xiaotong Guo or Guo X.
Selected publications
23 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Anticancer Drugs, 2025 (senior author): Pembrolizumab treatment in SMARCA4-deficient nonsmall cell lung cancer: high tumor mutational burden and programmed death-ligand 1(+) expression on circulating tumor cells for real-time monitoring: a case report. PubMed 40928867
- Discov Oncol, 2025 (first author): Single cell transcriptomic analysis reveals tumor immune infiltration by macrophage cells gene signature in lung adenocarcinoma. PubMed 40029500
- Clin Transl Med, 2024 (senior author): Single-cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers. PubMed 39601163
- Front Oncol, 2022 (senior author): Anatomical variation analysis of left upper pulmonary blood vessels and bronchi based on three-dimensional reconstruction of chest CT. PubMed 36479066
- Biomed Res Int, 2022 (senior author): LINC01426 Triggers Growth and Metastasis of Lung Adenocarcinoma as a Prognostic Indicator. PubMed 35620225
- Anticancer Drugs, 2022 (senior author): Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report. PubMed 35266890
- Am J Cancer Res, 2018 (first author): LncRNA LINC00163 upregulation suppresses lung cancer development though transcriptionally increasing TCF21 expression. PubMed 30662806
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion